Certolizumab pegol (Certolizumab) is a polyethylene glycolated and humanized anti-TNF-α monoclonal antibody for the study of autoimmune diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).

TNF-α:3 ng/mL (IC90)

Certolizumab pegol was able to neutralize soluble TNFα with an IC90 value of 3 ng/mL.Certolizumab pegol was able to completely inhibit IL-1β production by human monocytes in response to LPS stimulation after treatment at concentrations ranging from 0-100 μg/mL for 1 h. Certolizumab pegol does not mediate complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC). In addition, Certolizumab pegol does not induce apoptosis in activated human monocytes or peripheral blood lymphocytes (PBL), nor does it cause degranulation or disruption of cell membrane integrity in polymorphonuclear cells. [1]

Acute edematous pancreatitis was induced in healthy Wistar Albino male rats by intraperitoneal injection of 80 μg/kg of Cerulein (20 μg/kg each time for 4 doses, 1 hour apart). Subsequently, a single intraperitoneal injection of 10 μg Certolizumab pegol significantly reduced serum levels of amylase, lipase and lactate dehydrogenase. Histopathologic examination showed significant reductions in edema, hemorrhage, parenchymal necrosis, and infiltration scores. In addition, malondialdehyde, myeloperoxidase, TNF-α and caspase-3 activities were significantly reduced. [2]

Human

Monoclonal

Unconjugated